Intermediate

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia Α

BeCoMe–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Gene Therapy in Hemophilia – Novel and Emerging Therapies

Gene Therapy in Hemophilia: Clinical Care Strategies for Gene Therapy

Monthly Roundup: September 2024

Monthly Roundup: August 2024

Monthly Roundup: July 2024

Monthly Roundup: June 2024

Novel Approaches Under Investigation

Neutralizing Antibodies

Durability of Gene Therapy

Monthly Roundup

Interactive Webinars

Podcasts

Conference Coverage

Highlights From the 17th Annual Congress of EAHAD

Highlights From the 65th ASH Annual Meeting and Exposition

Highlights From the ESGCT 30th Annual Congress

Highlights From the 31st Congress of ISTH

Highlights From the 32nd Congress of ISTH

Gene Therapy Illustrated Clinical Trials

Microlearning

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL